Trial Profile

An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fondaparinux sodium (Primary) ; Fondaparinux sodium (Primary) ; Heparin
Indications Myocardial infarction
Focus Adverse reactions; Therapeutic Use
Acronyms OASIS-6
Sponsors GlaxoSmithKline

Most Recent Events

21 Mar 2020 Results examining whether machine learning could discover unknown associations from results of the OASIS-6 trial, in patients with ST-segment elevation myocardial infarctionpresented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
15 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com